Jinxin Reproduction (01951) The overall decline in the number of IVF egg retrieval cycles in 2025 narrowed further to -1.4%

According to Zhitong Finance App News, Jinxin Reproduction (01951) announced that in the fourth quarter of 2025, through continuous operational optimization measures, the number of in vitro fertilization (IVF) egg retrieval cycles of the group was further increased compared to the third quarter of 2025. Despite an 8.0% decline in the first half of 2025 compared to the same period in 2024, the Group's business in Greater China in 2025 still showed strong resilience. The annual results fell only slightly by 0.4% compared to 2024, and have basically recovered to the level of 2024.

For the year ended December 31, 2025, the Group's overall decline in IVF egg retrieval cycles narrowed further from -5.2% (between the first three quarters of 2024 to the first three quarters of 2025) to -1.4% (between the full year of 2024 and the full year of 2025). Among them, the number of IVF egg retrieval cycles at the Group's flagship hospital in Chengdu improved markedly, reversing from a -1.9% decline in the first three quarters of 2025 to a 1.3% year-on-year increase for the full year of 2025. Meanwhile, the number of IVF egg retrieval cycles in the Greater Bay Area narrowed from -13.5% decline in the first three quarters of 2025 to a decline of -5.9% throughout 2025. The number of IVF egg retrieval cycles in the Group's US and Laos overseas markets also narrowed from a decline of -10.8% in the first three quarters of 2025 to a decline of -6.9% throughout 2025.

Looking ahead to 2026 and beyond, the Group will continue to improve clinical treatment effectiveness, patient care quality and service supply level, accelerate the iterative upgrading of core reproductive medicine technology, deepen scientific research innovation and clinical transformation in the field of reproductive medicine, optimize medical treatment processes and digital service experience, further consolidate the regional market position of the flagship hospital in Chengdu, accelerate capacity release and market expansion after the relocation of the new hospital in the Greater Bay Area, and actively respond to changes in overseas policies and explore the potential for international market growth. Relying on the dividends of the national maternity support policy and industry development opportunities, the company will continue to consolidate its competitiveness, provide better medical services to patients, and ultimately create long-term stable value returns for shareholders and help the high-quality development of the industry.